Avoro Capital Advisors’s Altimmune ALT Stock Holding History

Avoro Capital Advisors’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,000,000	Closed	-$26.4M	–	45
2020 Q3	$26.4M	Buy	+2,000,000	New	+$40M	0.38%	31

Other funds holding ALT

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Avoro Capital Advisors's ALT Position: Q4 2020 in Review

Avoro Capital Advisors sold out of Altimmune (ALT) in Q4 2020, closing a stake of 2,000,000 shares — an estimated $26.4M sold.

Avoro Capital Advisors first reported a position in ALT in Q3 2020 and held it in 1 quarter. The position peaked at $26.4M in Q3 2020. 88 funds tracked by Wall St. Rank hold ALT as of Q4 2020.

Avoro Capital Advisors reported no remaining Altimmune position as of Q4 2020 after selling out during the quarter.
Avoro Capital Advisors sold 2,000,000 Altimmune shares in Q4 2020, an estimated $26.4M.
Avoro Capital Advisors first reported a position in Altimmune in Q3 2020 and held it in 1 quarter.
Avoro Capital Advisors's Altimmune position peaked at $26.4M in Q3 2020.
88 funds tracked by Wall St. Rank held Altimmune as of Q4 2020.

Based on Avoro Capital Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.